Navigation Links
InterMune to Release Third Quarter 2008 Financial Results on November 6
Date:10/28/2008

BRISBANE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release third quarter 2008 financial results on Thursday, November 6, 2008 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 71184785. To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 71184785.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
2. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
3. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
4. InterMune to Present at Canaccord Adams Conference
5. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
6. InterMune to Present at BMO Healthcare Conference
7. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
8. InterMune to Present at Jefferies Healthcare Conference
9. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
10. InterMune to Present at Citigroup Healthcare Conference
11. InterMune to Present at Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... 02, 2019 , ... eKare’s inSight® digital 3D imaging and wound measurement system ... East Midlands Academic Health Science Network (EMAHSN), the innovation arm of the NHS. The ... support to develop and deploy solutions to the most pressing challenges facing the NHS. ...
(Date:9/24/2019)... ... September 24, 2019 , ... Drug resistance has been declared as one ... with MRSA becoming one of the most serious concerns. Hong Kong cannot be spared ... community-associated MRSA (CA-MRSA), or a seven-fold of the figure in 2007 – the year ...
(Date:9/22/2019)... (PRWEB) , ... September 20, 2019 , ... ... launch of Brain-Derived Neurotrophic Factor (BDNF) testing in serum . BDNF plays ... systems. BDNF stimulates the growth and differentiation of new neurons in the brain ...
(Date:9/17/2019)... STATION, N.J. (PRWEB) , ... September 16, 2019 , ... ... clearing reagents and kits that allow for the complete 3D characterization of tissues through ... Visikol has transitioned into an imaging, image analysis and advanced cell culture focused contract ...
Breaking Biology Technology:
(Date:10/4/2019)... ... , ... Representatives with MyBioGate ( https://events.mybiogate.com/ ) announced that ... Rothenbaumchaussee in Hamburg. , “To better connect Chinese companies and European markets, China ... Operations and spokesperson for MyBioGate. , Guo went on to highlight that China ...
(Date:10/3/2019)... ... October 02, 2019 , ... Personalized Stem Cells, ... patient in an FDA approved clinical trial for stem cell treatment of knee ... formation of the company as a subsidiary of VetStem Biopharma. , PSC CEO, Michael ...
(Date:9/30/2019)... ... September 30, 2019 , ... ... increasing the capacity of life science organizations to accelerate innovation and maximize productivity, ... on October 4th. , What: Just 30 days to 21 CFR Part 11 ...
Breaking Biology News(10 mins):